Skip to main content



) --

Alexion Pharmaceuticals Incorporated



) hit a new 52-week high Monday as it traded at $96.94 compared with its previous 52-Week high of $95.50. Alexion is changing hands at $94.88 with 31,118 shares traded as of 9:30 a.m. ET. Average volume has been 793,300 shares over the past 30 days.

Alexion has a market cap of $8.4 billion and is part of the

health care

sector and


TheStreet Recommends

industry. Shares are up 17.8% year to date as of the close of trading on Friday.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. The company has a P/E ratio of 88.6, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 22.6.

TheStreet Ratings rates Alexion as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full

Alexion Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center